After investigating America’s supply chains, including those for drugs and pharmaceutical ingredients, the Biden administration has revelations to share—and it’s proposing a sweeping strategy to boost domestic drug production.
Under the plan, the White House is establishing a public-private partnership to select 50 to 100 essential medicines “to be the focus of an enhanced onshoring effort,” the plan says. Further, the government is committing around $60 million to research new technologies to boost domestic API production.